Trial Evaluating an Investigational Agent for Management of Oral Melanoma in Dogs - Richmond Location
CURRENTLY ENROLLING
This trial is designed to evaluate the effectiveness of a novel therapy in dogs with oral melanoma.
Trial Evaluating an Investigational Agent for Management of Oral Melanoma in Dogs - Springfield Location
CURRENTLY ENROLLING
This trial is designed to evaluate the effectiveness of a novel therapy in dogs with oral melanoma.
Evaluating the Tolerability of Combination of Verdinexor and Doxorubicin in Dogs with Cancer - Richmond Location
Verdinexor is a chemotherapy drug that has been conditionally approved by the FDA for the treatment of canine lymphoma. Verdinexor is a selective inhibitor of nuclear export (SINE) compound, and this family of drug has demonstrated encouraging results in preclinical studies when combined with other chemotherapeutic drugs.
Trial Evaluating an Investigational Agent for Management of Transitional Cell Carcinoma - Richmond Location
CLOSEDThis trial is designed to evaluate the safety and preliminary pain management and anti-cancer effectiveness of a novel therapy in dogs with bladder transitional cell carcinoma (TCC).